This is consistent with recent reports that glioma cells are defective in NAD+ biosynthesis, especially for those with IDH1 somatic mutations (86) and suggests a major factor in the regulation of PARP1 signaling in GSCs and glioma cells may be related to a defect in NAD+ biosynthesis. The gene discussed is IDH1; the disease is central nervous system cancer.